D.A. Davidson & CO. Buys 205 Shares of Humana Inc. (NYSE:HUM)

D.A. Davidson & CO. boosted its stake in Humana Inc. (NYSE:HUM) by 19.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,283 shares of the insurance provider’s stock after acquiring an additional 205 shares during the period. D.A. Davidson & CO.’s holdings in Humana were worth $326,000 as of its most recent filing with the SEC.

Several other hedge funds have also added to or reduced their stakes in HUM. AMF Tjanstepension AB raised its position in Humana by 166.8% in the third quarter. AMF Tjanstepension AB now owns 40,051 shares of the insurance provider’s stock worth $12,686,000 after acquiring an additional 25,041 shares during the period. Assenagon Asset Management S.A. raised its position in Humana by 12.7% in the third quarter. Assenagon Asset Management S.A. now owns 4,090 shares of the insurance provider’s stock worth $1,295,000 after acquiring an additional 461 shares during the period. DekaBank Deutsche Girozentrale raised its position in Humana by 7.4% in the third quarter. DekaBank Deutsche Girozentrale now owns 55,702 shares of the insurance provider’s stock worth $17,652,000 after acquiring an additional 3,862 shares during the period. Your Advocates Ltd. LLP raised its position in Humana by 81.8% in the third quarter. Your Advocates Ltd. LLP now owns 100 shares of the insurance provider’s stock worth $32,000 after acquiring an additional 45 shares during the period. Finally, AustralianSuper Pty Ltd raised its position in Humana by 35.2% in the third quarter. AustralianSuper Pty Ltd now owns 2,495 shares of the insurance provider’s stock worth $790,000 after acquiring an additional 650 shares during the period. Institutional investors own 92.38% of the company’s stock.

Insider Activity

In other news, insider Timothy S. Huval sold 3,703 shares of the company’s stock in a transaction on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the completion of the sale, the insider now owns 8,181 shares of the company’s stock, valued at approximately $2,096,463.06. This represents a 31.16 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. 0.32% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. StockNews.com raised shares of Humana from a “hold” rating to a “buy” rating in a research report on Tuesday. Wells Fargo & Company lowered their price target on shares of Humana from $387.00 to $290.00 and set an “overweight” rating on the stock in a research report on Monday, November 4th. TD Cowen boosted their price target on shares of Humana from $261.00 to $268.00 and gave the company a “hold” rating in a research report on Monday, November 4th. Royal Bank of Canada reissued an “outperform” rating and issued a $283.00 price target on shares of Humana in a research report on Wednesday, February 12th. Finally, Cantor Fitzgerald reissued a “neutral” rating and issued a $290.00 price target on shares of Humana in a research report on Wednesday, February 12th. Nineteen investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Hold” and an average price target of $285.68.

Humana Price Performance

HUM stock opened at $255.06 on Thursday. The company has a debt-to-equity ratio of 0.68, a current ratio of 1.76 and a quick ratio of 1.76. Humana Inc. has a one year low of $213.31 and a one year high of $406.46. The stock has a market cap of $30.77 billion, a PE ratio of 25.63, a P/E/G ratio of 2.05 and a beta of 0.56. The firm has a 50 day simple moving average of $270.12 and a two-hundred day simple moving average of $288.06.

Humana (NYSE:HUM) last released its quarterly earnings results on Tuesday, February 11th. The insurance provider reported ($2.16) EPS for the quarter, topping analysts’ consensus estimates of ($2.26) by $0.10. Humana had a net margin of 1.02% and a return on equity of 11.70%. On average, analysts predict that Humana Inc. will post 16.47 EPS for the current fiscal year.

Humana Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, April 25th. Stockholders of record on Friday, March 28th will be paid a $0.885 dividend. The ex-dividend date of this dividend is Friday, March 28th. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.39%. Humana’s dividend payout ratio (DPR) is 35.58%.

Humana Profile

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.